Td Waterhouse Canada Inc. Aldeyra Therapeutics, Inc. Transaction History
Td Waterhouse Canada Inc.
- $12.2 Trillion
- Q1 2025
A detailed history of Td Waterhouse Canada Inc. transactions in Aldeyra Therapeutics, Inc. stock. As of the latest transaction made, Td Waterhouse Canada Inc. holds 15 shares of ALDX stock, worth $80. This represents 0.0% of its overall portfolio holdings.
Number of Shares
15
Previous 15
-0.0%
Holding current value
$80
Previous $75,000
9.33%
% of portfolio
0.0%
Previous 0.0%
Shares
1 transactions
Others Institutions Holding ALDX
# of Institutions
142Shares Held
38.9MCall Options Held
620KPut Options Held
435K-
Perceptive Advisors LLC New York, NY9.28MShares$49.7 Million2.23% of portfolio
-
Knoll Capital Management, LLC Miami, FL5.48MShares$29.3 Million21.03% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.72MShares$19.9 Million0.0% of portfolio
-
Black Rock Inc. New York, NY3.62MShares$19.4 Million0.0% of portfolio
-
Ardsley Advisory Partners LP Stamford, CT1.75MShares$9.38 Million2.26% of portfolio
About Aldeyra Therapeutics, Inc.
- Ticker ALDX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 58,323,100
- Market Cap $313M
- Description
- Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It al...